About CATALIS
CATALIS is a company based in Montreal (Canada) founded in 2017. CATALIS has raised $1.18 million across 1 funding round from investors including Merck, AbbVie and Pfizer. CATALIS offers products and services including FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec. CATALIS operates in a competitive market with competitors including MCRA, Blue Matter Consulting, CHDR, PharmAla Biotech and Aptus Clinical, among others.
- Headquarter Montreal, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.18 M (USD)
in 1 rounds
-
Latest Funding Round
$1.18 M (USD), Seed
Jun 03, 2019
-
Investors
Merck
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CATALIS
CATALIS offers a comprehensive portfolio of products and services, including FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec.
Accelerates authorization for clinical trials in Quebec
Offers tailored assistance for clinical research stakeholders
Facilitates tools and resources for conducting clinical trials
Funding Insights of CATALIS
CATALIS has successfully raised a total of $1.18M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.18 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CATALIS
CATALIS has secured backing from 8 investors, including institutional investors. Prominent investors backing the company include Merck, AbbVie and Pfizer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
Locked | Locked | Locked | |
|
Pharmaceutical products for treating multiple diseases are provided.
|
Locked | Locked | Locked | |
|
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Locked | Locked | Locked |
Investor details for CATALIS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CATALIS
Investment portfolio details for CATALIS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CATALIS
Detailed financials for CATALIS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Catalis Comparisons
Peer comparison for CATALIS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CATALIS
CATALIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MCRA, Blue Matter Consulting, CHDR, PharmAla Biotech and Aptus Clinical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of regulatory, quality assurance and market access services to biopharma sector
|
|
| Locked | Locked | Locked |
Provider of consulting services focused for clinical drug development
|
|
| Locked | Locked | Locked |
Early-stage clinical drug research consulting services are provided.
|
|
| Locked | Locked | Locked |
Biomanufacturing, regulatory, and financial services are provided by PharmAla Biotech.
|
|
| Locked | Locked | Locked |
Auxiliary clinical development services are provided to biopharmaceutical firms.
|
Detailed competitors of CATALIS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Catalis
Complete news archive for CATALIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CATALIS
CATALIS was founded in 2017 and raised its 1st funding round 2 years after it was founded.
CATALIS is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
CATALIS is a funded company, having raised a total of $1.18M across 1 funding round to date.
CATALIS was founded in 2017 in Montreal, Canada, as a provider of consulting services in the biopharmaceutical sector. Operations center on clinical drug development, with support for phase I, II, and III trials. Expertise is applied to pharmacology, biomarkers, and biopharmaceutical devices, assisting clients in regulatory and operational aspects of drug advancement. Services are delivered to facilitate efficient trial execution and development processes.
CATALIS's top competitors include S-Cubed, Blue Matter Consulting and PharmAla Biotech.
CATALIS offers FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec.